Skip to content
Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies

  • Post published:March 23, 2021
  • Post category:Analysis/Editorial
Read more about the article Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

  • Post published:March 2, 2021
  • Post category:Analysis/News
Read more about the article Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders

Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders

  • Post published:February 16, 2021
  • Post category:Analysis/Editorial
Read more about the article UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

  • Post published:January 27, 2021
  • Post category:Analysis/News
Read more about the article North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF?

  • Post published:January 21, 2021
  • Post category:Analysis/News
Read more about the article The Psychedelic Renaissance in 2020

The Psychedelic Renaissance in 2020

  • Post published:December 30, 2020
  • Post category:Analysis/Editorial
Read more about the article First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK)

  • Post published:December 28, 2020
  • Post category:Analysis/News
Read more about the article Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment

  • Post published:December 12, 2020
  • Post category:Analysis/News
Read more about the article Cybin Corp Establishes a Firm Foothold in the Psychedelic Sector with Historic CAD$45 Million Raise

Cybin Corp Establishes a Firm Foothold in the Psychedelic Sector with Historic CAD$45 Million Raise

  • Post published:October 30, 2020
  • Post category:Analysis/Editorial
Read more about the article Psilocybin Patents: Predictors and Drivers of Company Value?

Psilocybin Patents: Predictors and Drivers of Company Value?

  • Post published:September 26, 2020
  • Post category:Analysis

End of content

No more pages to load

← Newer Posts

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More